WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association
WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association for Cancer Research DrLana Kandalaftfrom the University of Pennsylvania in Philadelphia explained this was the first time a combination of dendritic cell vaccination and adoptive T-cell therapy had been used in ovarian cancer and that it was successful, even producing a complete remission in one patient and had few — if any — side effects. She discussed the therapy with Peter Goodwin.
Related Episodes
Victor Velculescu MD PhD: Ovarian Cancer Noninvasive Detection by Circulating DNA Fragmentome and Protein Biomarker AI Analysis
Victor E Velculescu MD PhD
Timothy Yap MD PhD MBBS: Selective PARP1 Inhibitor Saruparib Clinical Promise in Solid Tumors with Homologous Recombination Repair Deficiency
Timothy Yap MD PhD MBBS selective PARP inhibitor promise in breast, ovarian, pancreatic, prostate tumors.
